Results 101 to 110 of about 21,323 (200)

Immunotherapy using pullulan‐conjugated Der f 2 allergen in canine atopic dermatitis: An anti‐inflammatory agent‐sparing approach

open access: yesVeterinary Dermatology, EarlyView.
Background – Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD). Objective – To assess the anti‐inflammatory agent‐sparing effect over 1 year of immunotherapy using pullulan‐conjugated recombinant Der f 2 (rDf2‐P). Conclusions and Clinical Relevance – Der f 2‐P immunotherapy can lead to a rapid reduction in anti‐
Masahiko Nagata   +7 more
wiley   +1 more source

Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client‐owned dogs: A multicentre, double‐masked, randomised, placebo‐controlled clinical trial

open access: yesVeterinary Dermatology, EarlyView.
Background – Inhibition of the Janus kinase (JAK) pathway is a well‐established option for canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, a novel JAK inhibitor for the control of pruritus and skin lesions in client‐owned dogs with cAD.
Sophie Forster   +5 more
wiley   +1 more source

Effects of Oral Macrocyclic Lactone Heartworm Preventatives on Retinal Function and Chromatic Pupillary Light Reflex in Healthy Companion Dogs

open access: yesVeterinary Ophthalmology, EarlyView.
ABSTRACT Objective Determine the effect of oral macrocyclic lactone heartworm‐preventative medications on retinal function and chromatic pupillary light reflex (cPLR) in healthy dogs. Animals Studied Cross‐sectional retrospective: 60 dogs (n = 33 females) with heartworm medication administration status and electroretinogram (ERG) data available ...
Ryan G. Hopper   +6 more
wiley   +1 more source

New Pyridobenothiazolone Derivatives Display Nanomolar Pan‐Serotype Anti‐Dengue Virus Activity

open access: yesChemMedChem, Volume 20, Issue 13, July 1, 2025.
A ligand‐based strategy is employed, starting from hit compound 2, to develop the C‐2 modified pyridobenzothiazolone 19 as a pan‐serotype nanomolar DENV‐1‐4 inhibitor. Investigations of the mechanism reveal the peculiar ability to abolish the infectivity of virions in a second infection.
Tommaso Felicetti   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy